Clinical trials: Respiratory Tract Infection
Influenza
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
To describe the safety of the inactivated, split-virion influenza vaccine, 2008-2009 formulation. To evaluate the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine 2008-2009 formulation…
- Trial name
- NCT00743275
- Testing
- Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tetanus, Hepatitis B
Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants
The primary purpose of this study is to demonstrate the lot-to-lot consistency of 3 production lots of GSK Biologicals' Hib-MenAC (Haemophilus influenzae type b and meningococcal serogroups A and C) vaccine when reconstituted…
- Conditions
- Tetanus, Hepatitis B, Haemophilus Influenzae Type b, Whole Cell Pertussis
- Trial name
- NCT00197275
- Testing
- Hib-MenAC mixed with Tritanrix™-HepB
- Where
- 3 sites in Thailand
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.
The purpose of this study is to collect safety information on the use of Fluarix Tetra according to the approved PI, in Korea, over a period of 6 years from children greater than or equal to (≥)3 years of age and adults, and over…
- Trial name
- NCT02663102
- Testing
- Data collection
- Where
- 21 sites in South Korea
- Volunteers
- 1,388 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID -19, Influenza A
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus
- Trial name
- NCT07217639
- Testing
- Aptitude Medical Systems Respiratory Panel Test
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Aptitude Medical Systems
Influenza
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
This study is a global multicenter randomized factorial double-blind, placebo-controlled trial designed to evaluate (i) efficacy and safety of nitazoxanide 600 mg administered orally twice daily for five days compared to a…
- Trial name
- NCT01610245
- Testing
- Nitazoxanide, Oseltamivir
- Where
- 167 sites in United States, Australia and 3 more
- Volunteers
- 1,941 people
- Sponsor
- Romark Laboratories L.C.
COVID-19 Respiratory Infection, SARS-CoV-2 Acute Respiratory Disease
Photodynamic Therapy for COVID-19 Prevention
This is a single-center open-label study to evaluate antimicrobial photodynamic therapy (aPDT) for upper airway decolonization in patients presenting with SARS-CoV-2 positive antigen test with mild or no symptoms of COVID-19.
- Trial name
- NCT05184205
- Testing
- Nasal Photodisinfection
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Ondine Biomedical Inc.
Covid19
Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]
The Prevent-COVID study is a prospective, multicenter, randomized, two-armed, placebo-controlled, double-blind, interventional study in which the efficacy and safety of ivermectin in COVID-19 post-exposure prophylaxis (PEP) is…
- Trial name
- NCT05060666
- Testing
- Ivermectin
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- Infectopharm Arzneimittel GmbH
Respiratory Syncytial Virus Infections
A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
The purpose of the study is to learn about the safety and amount of sisunatovir in the blood of infants and children up to age 60 months.
- Trial name
- NCT06102174
- Testing
- Active
- Where
- 9 sites in United States, Japan and 1 more
- Volunteers
- 10 people
- Sponsor
- Pfizer
Influenza
Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program
To measure the effectiveness of influenza vaccination in school children by comparing, between target(i.e., children are offered FluMist) and control (i.e., children are not offered FluMist) school families.
- Trial name
- NCT00192218
- Testing
- FluMist
- Where
- 2 sites in United States
- Volunteers
- 3,022 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management…
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
- Trial name
- PREVAIL (NCT05472090)
- Testing
- TNX-102 SL
- Where
- 29 sites in United States
- Volunteers
- 63 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Rhinitis, Sinusitis
A Study of Luffa Operculate Nasal Solution 5mg/mL Compared With Saline (NaCl 09%) for the Relief of Nasal Obstruction
Sixty subjects will take part in this study. The subjects will be randomly assigned in a 1:1 ratio between the two arms of study. (Group A: Solution of Luffa Nasal Operculate 5mg/mL, Group B: saline).
- Trial name
- NCT01248325
- Testing
- Luffa Operculate Nasal Solution 5mg/mL, Saline Solution (NaCl 0,9%)
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Zurita Laboratorio Farmaceutico Ltda.
Healthy Participants
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 [CYP]3A4 substrate) in Healthy Adult Participants.
- Trial name
- NCT05032950
- Testing
- Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of STI-1558 in adult subjects with mild/moderate COVID-19.
- Trial name
- NCT05716425
- Testing
- STI-1558
- Where
- 2 sites in China
- Volunteers
- 1,218 people
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
Severe Acute Respiratory Syndrome, Coronavirus
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
- Conditions
- Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
- Trial name
- NCT04449276
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- CureVac
Covid19
Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects
This study will assess the safety, tolerability and immunogenicity of DS-5670a (COVID-19 Vaccine) and determine the recommended dose in Japanese healthy adults and elderly participants.
- Trial name
- NCT04821674
- Testing
- DS-5670a
- Where
- Japan
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Influenza
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)
The aim of this study is to evaluate the new formulation of the influenza vaccine for the 2010-2011 Northern Hemisphere (NH) season in terms of immunogenicity and safety in the corresponding population and to check its compliance…
- Trial name
- NCT01138397
- Testing
- Influenza virus vaccine (split virion, inactivated)
- Where
- 2 sites in Belgium
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A Virus Infection
Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment
This study aims to evaluate the safety and effect of interferon-alpha lozenges when used in combination with oseltamivir (Tamiflu) to treat influenza.
- Trial name
- NCT01146535
- Testing
- Interferon-alpha, Oseltamivir, maltose
- Where
- 4 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
COVID-19
A Study of Silmitasertib (CX-4945) in Healthy Subject
This is a Phase I single center, open-label, parallel design in 30 subjects to evaluate safety and tolerability of CX-4945 200mg QD, 200 mg BID and 400mg BID doses (10 subjects in each regimen) for continuously 5 days in healthy…
- Trial name
- NCT05817708
- Testing
- CX-4945
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Senhwa Biosciences, Inc.
RSV Infection
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
- Trial name
- NCT06843317
- Testing
- Candidate vaccine, SCB-1019T, AREXVY
- Where
- 5 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals USA, LLC
Acute Anterior Myocardial Infarction
Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to Percutaneous Coronary Intervention
Rapid MI-ICE-Pilot is designed to demonstrate the safety and efficacy of the Celsius Control™ System (CCS) endovascular catheter to reduce the infarct size resulting from acute anterior myocardial infarction when used in…
- Trial name
- NCT00417638
- Testing
- Endovascular cooling by the Celsius Control System, Standard of care
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- ZOLL Circulation, Inc., USA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.